09.01.2020 • NewsElaine BurridgeAstellas

Astellas Acquires Xyphos Biosciences

Astellas Acquires Xyphos Biosciences (c) Xyphos Biosciences
Astellas Acquires Xyphos Biosciences (c) Xyphos Biosciences

Japanese drugmaker Astellas Pharma has boosted its immuno-oncology capabilities with the purchase of US-based Xyphos Biosciences. The acquisition was the second last month for the Tokyo-based pharma, which had also agreed to buy US gene therapy company Audentes Therapeutics for $3 billion.

The deal, which is worth up to $665 million, gives Astellas access to Xyphos’s novel ACCEL (Advanced Celllular Control through Engineered Ligands) technology platform. 

“Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology,” said Astellas president and CEO Kenji Yasukawa.

Xyphos’s proprietary molecules can be delivered to natural immune cells or to engineered Chimeric Antigen Receptor (CAR) cells to generate immunotherapies for oncology.   Xyphos’ first CAR-T cell product candidate is in preclinical development and scheduled to be tested in a first-in-human clinical study in 2021.

Astellas paid $120 million upfront and will pay the rest on future development milestones being met.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.